UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $6.00 | Buy | Craig Hallum |
| 10/7/2024 | $4.00 | Neutral | UBS |
| 2/25/2022 | $3.00 → $2.50 | Market Perform | SVB Leerink |
| 2/2/2022 | $7.00 → $3.00 | Underperform → Market Perform | Cowen & Co. |
| 2/2/2022 | $6.00 | Buy | Canaccord Genuity |
| 1/19/2022 | $3.00 | Market Perform | SVB Leerink |
| 1/10/2022 | $9.00 → $3.50 | Neutral | Citigroup |
| 1/7/2022 | $9.00 → $3.50 | Neutral → Underperform | Credit Suisse |
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
SAN FRANCISCO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI‑powered physician‑enablement platform, today announced the next step in the evolution of its flagship Counterpart Assistant (CA): generative AI capabilities that let clinicians engage with a patient's longitudinal data in real time through AI chat. Instead of digging through countless clinical documents when researching patients, clinicians can now ask questions about a patient's medical history in natural language within a protected health information (PHI)-safe
WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial
WILMINGTON, Del., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, is leveraging Availity, the nation's largest real-time health information network, for a multi-phase initiative designed to increase operational efficiency across administrative functions for providers while improving patient access to timely, quality care. Across the healthcare system, providers face significant challenges managing prior authorizations, eligibility checks, and claims. These processes can take the focus away from patient care
Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00
UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage
WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Second Quarter 2025 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2025 Earnings Conference CallWhen: Tuesday, August 5, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-245-3047 (for U.S. caller
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year
WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten
WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function. Mr. Oldakowski, who joined Clover Health in June, brings nearly two decades of experience in finance and accounting leadership across the healthcare and insurance sectors. He most recently served a
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso